Neuropace Inc Financials
This page shows Neuropace Inc (NPCE) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue scale-up is steadily narrowing losses because this is an asset-light, high-gross-margin business still carrying heavy operating spend.
From FY2022 to FY2025, revenue rose from$45.5M to$100.0M while gross margin improved from71.4% to77.2% and free cash burn fell from-$37.5M to-$11.3M . Because capital spending stayed tiny at just$332K in FY2025, the gap to breakeven is being driven far more by operating expense than by a product that is structurally expensive to deliver.
Cash conversion is fairly transparent: FY2025 operating cash flow was
The balance sheet is more comfortable on liquidity than on leverage: the current ratio was 5.3x and cash was
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Neuropace Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Neuropace Inc scores -2.01, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($578.6M) relative to total liabilities ($86.5M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Neuropace Inc passes 5 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Neuropace Inc generates $0.51 in operating cash flow (-$11.0M OCF vs -$21.5M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Neuropace Inc earns $-2.2 in operating income for every $1 of interest expense (-$16.3M vs $7.5M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Neuropace Inc generated $100.0M in revenue in fiscal year 2025. This represents an increase of 25.1% from the prior year.
Neuropace Inc's EBITDA was -$16.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 25.0% from the prior year.
Neuropace Inc reported -$21.5M in net income in fiscal year 2025. This represents an increase of 20.9% from the prior year.
Neuropace Inc earned $-0.66 per diluted share (EPS) in fiscal year 2025. This represents an increase of 29.0% from the prior year.
Cash & Balance Sheet
Neuropace Inc generated -$11.3M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 37.9% from the prior year.
Neuropace Inc held $21.7M in cash against $58.9M in long-term debt as of fiscal year 2025.
Neuropace Inc paid $0.00 per share in dividends in fiscal year 2025.
Neuropace Inc had 34M shares outstanding in fiscal year 2025. This represents an increase of 11.4% from the prior year.
Margins & Returns
Neuropace Inc's gross margin was 77.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 3.3 percentage points from the prior year.
Neuropace Inc's operating margin was -16.3% in fiscal year 2025, reflecting core business profitability. This is up 10.8 percentage points from the prior year.
Neuropace Inc's net profit margin was -21.5% in fiscal year 2025, showing the share of revenue converted to profit. This is up 12.5 percentage points from the prior year.
Neuropace Inc's ROE was -112.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 225.9 percentage points from the prior year.
Capital Allocation
Neuropace Inc invested $27.9M in research and development in fiscal year 2025. This represents an increase of 17.9% from the prior year.
Neuropace Inc spent $49.5M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding.
Neuropace Inc invested $332K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 8.5% from the prior year.
NPCE Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $22.1M-17.0% | $26.6M-2.8% | $27.4M+16.3% | $23.5M+4.4% | $22.5M+4.9% | $21.5M+1.9% | $21.1M+9.4% | $19.3M |
| Cost of Revenue | $4.0M-33.1% | $6.0M-2.8% | $6.2M+14.8% | $5.4M+4.0% | $5.2M-1.8% | $5.3M-6.4% | $5.6M+10.1% | $5.1M |
| Gross Profit | $18.0M-12.3% | $20.6M-2.8% | $21.2M+16.7% | $18.1M+4.6% | $17.3M+7.1% | $16.2M+5.0% | $15.4M+9.1% | $14.1M |
| R&D Expenses | $7.2M+2.3% | $7.0M+6.9% | $6.6M-3.9% | $6.8M-8.0% | $7.4M+23.0% | $6.0M+5.1% | $5.8M-5.1% | $6.1M |
| SG&A Expenses | $4.8M+173.2% | -$6.6M-244.1% | $4.6M-24.3% | $6.1M-59.7% | $15.0M+9.1% | $13.8M-0.8% | $13.9M-2.7% | $14.3M |
| Operating Income | -$5.6M-215.1% | -$1.8M+32.0% | -$2.6M+61.9% | -$6.8M-32.6% | -$5.1M-40.9% | -$3.7M+13.9% | -$4.2M+31.9% | -$6.2M |
| Interest Expense | $1.5M-4.9% | $1.6M-2.7% | $1.6M-20.1% | $2.1M-4.4% | $2.2M-1.8% | $2.2M+0.5% | $2.2M+0.7% | $2.2M |
| Income Tax | $0 | $0 | $0 | $0 | $0 | N/A | $0 | $0 |
| Net Income | -$6.7M-145.1% | -$2.7M+21.9% | -$3.5M+59.6% | -$8.7M-31.3% | -$6.6M-25.5% | -$5.3M+3.7% | -$5.5M+27.4% | -$7.5M |
| EPS (Diluted) | $-0.20 | N/A | $-0.11+57.7% | $-0.26-23.8% | $-0.21 | N/A | $-0.19+26.9% | $-0.26 |
NPCE Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $98.9M-6.3% | $105.6M-1.6% | $107.3M+1.1% | $106.1M-3.7% | $110.2M+16.4% | $94.6M-1.7% | $96.3M+2.0% | $94.4M |
| Current Assets | $87.0M-7.5% | $94.1M-1.3% | $95.3M+1.7% | $93.7M-3.8% | $97.5M+19.8% | $81.3M-1.5% | $82.6M+2.9% | $80.2M |
| Cash & Equivalents | $14.8M-31.9% | $21.7M+5.1% | $20.6M-9.7% | $22.9M-15.4% | $27.0M+101.2% | $13.4M-12.9% | $15.4M+20.0% | $12.8M |
| Inventory | $16.7M-1.2% | $16.9M-6.8% | $18.1M+10.9% | $16.3M+20.4% | $13.6M+1.5% | $13.4M+10.7% | $12.1M+6.3% | $11.4M |
| Accounts Receivable | $14.8M+0.7% | $14.7M-1.7% | $14.9M+10.2% | $13.6M-12.2% | $15.4M+20.1% | $12.9M+11.2% | $11.6M+2.8% | $11.2M |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $84.4M-2.4% | $86.5M-2.5% | $88.7M+2.4% | $86.7M+0.9% | $85.9M-0.8% | $86.6M+0.2% | $86.5M+2.3% | $84.5M |
| Current Liabilities | $16.2M-9.2% | $17.8M-9.1% | $19.6M+14.4% | $17.1M+16.6% | $14.7M-3.0% | $15.2M+2.5% | $14.8M+17.4% | $12.6M |
| Long-Term Debt | $59.0M+0.2% | $58.9M+0.2% | $58.7M+0.2% | $58.6M-2.0% | $59.8M+0.4% | $59.5M+0.4% | $59.3M+0.4% | $59.0M |
| Total Equity | $14.5M-24.1% | $19.0M+2.8% | $18.5M-4.7% | $19.4M-19.9% | $24.3M+202.9% | $8.0M-18.4% | $9.8M-0.6% | $9.9M |
| Retained Earnings | -$559.1M-1.2% | -$552.4M-0.5% | -$549.7M-0.6% | -$546.2M-1.6% | -$537.5M-1.2% | -$531.0M-1.0% | -$525.7M-1.0% | -$520.2M |
NPCE Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$5.9M-1266.0% | $506K+126.0% | -$1.9M+6.8% | -$2.1M+72.1% | -$7.5M-56.0% | -$4.8M-178.2% | -$1.7M+55.8% | -$3.9M |
| Capital Expenditures | $117K+20.6% | $97K+223.3% | $30K-82.1% | $168K+354.1% | $37K-5.1% | $39K-61.0% | $100K+58.7% | $63K |
| Free Cash Flow | -$6.0M-1571.1% | $409K+120.7% | -$2.0M+12.4% | -$2.3M+70.0% | -$7.5M-55.5% | -$4.8M-165.1% | -$1.8M+54.0% | -$4.0M |
| Investing Cash Flow | -$117K-20.6% | -$97K-223.3% | -$30K+82.1% | -$168K-354.1% | -$37K-101.9% | $2.0M+40.1% | $1.4M-56.8% | $3.2M |
| Financing Cash Flow | -$166K-126.1% | $635K+370.2% | -$235K+87.7% | -$1.9M-109.0% | $21.1M+2389.2% | $848K-70.7% | $2.9M+469.4% | $509K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | $0 | $0 | $0 | $0-100.0% | $49.5M | $0 | $0 | $0 |
NPCE Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 81.8%+4.4pp | 77.4%0.0pp | 77.4%+0.3pp | 77.1%+0.1pp | 77.0%+1.6pp | 75.4%+2.2pp | 73.2%-0.2pp | 73.4% |
| Operating Margin | -25.2%-18.6pp | -6.7%+2.9pp | -9.5%+19.5pp | -29.0%-6.2pp | -22.9%-5.8pp | -17.0%+3.1pp | -20.2%+12.2pp | -32.4% |
| Net Margin | -30.3%-20.0pp | -10.3%+2.5pp | -12.8%+24.0pp | -36.8%-7.5pp | -29.3%-4.8pp | -24.5%+1.4pp | -25.9%+13.1pp | -39.0% |
| Return on Equity | -46.3%-31.9pp | -14.3%+4.5pp | -18.9%+25.6pp | -44.5%-17.4pp | -27.2%+38.4pp | -65.5%-10.0pp | -55.5%+20.5pp | -76.0% |
| Return on Assets | -6.8%-4.2pp | -2.6%+0.7pp | -3.3%+4.9pp | -8.2%-2.2pp | -6.0%-0.4pp | -5.5%+0.1pp | -5.7%+2.3pp | -8.0% |
| Current Ratio | 5.38+0.1 | 5.28+0.4 | 4.86-0.6 | 5.47-1.2 | 6.63+1.3 | 5.37-0.2 | 5.59-0.8 | 6.37 |
| Debt-to-Equity | 4.08+1.0 | 3.09-0.1 | 3.17+0.2 | 3.02+0.6 | 2.46-5.0 | 7.43+1.4 | 6.03+0.1 | 5.97 |
| FCF Margin | -27.3%-28.8pp | 1.5%+8.8pp | -7.2%+2.4pp | -9.6%+23.8pp | -33.4%-10.8pp | -22.5%-13.9pp | -8.7%+11.9pp | -20.6% |
Similar Companies
Frequently Asked Questions
What is Neuropace Inc's annual revenue?
Neuropace Inc (NPCE) reported $100.0M in total revenue for fiscal year 2025. This represents a 25.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Neuropace Inc's revenue growing?
Neuropace Inc (NPCE) revenue grew by 25.1% year-over-year, from $79.9M to $100.0M in fiscal year 2025.
Is Neuropace Inc profitable?
No, Neuropace Inc (NPCE) reported a net income of -$21.5M in fiscal year 2025, with a net profit margin of -21.5%.
What is Neuropace Inc's EBITDA?
Neuropace Inc (NPCE) had EBITDA of -$16.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Neuropace Inc have?
As of fiscal year 2025, Neuropace Inc (NPCE) had $21.7M in cash and equivalents against $58.9M in long-term debt.
What is Neuropace Inc's gross margin?
Neuropace Inc (NPCE) had a gross margin of 77.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Neuropace Inc's operating margin?
Neuropace Inc (NPCE) had an operating margin of -16.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Neuropace Inc's net profit margin?
Neuropace Inc (NPCE) had a net profit margin of -21.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Neuropace Inc's return on equity (ROE)?
Neuropace Inc (NPCE) has a return on equity of -112.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Neuropace Inc's free cash flow?
Neuropace Inc (NPCE) generated -$11.3M in free cash flow during fiscal year 2025. This represents a 37.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Neuropace Inc's operating cash flow?
Neuropace Inc (NPCE) generated -$11.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Neuropace Inc's total assets?
Neuropace Inc (NPCE) had $105.6M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Neuropace Inc's capital expenditures?
Neuropace Inc (NPCE) invested $332K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Neuropace Inc spend on research and development?
Neuropace Inc (NPCE) invested $27.9M in research and development during fiscal year 2025.
What is Neuropace Inc's current ratio?
Neuropace Inc (NPCE) had a current ratio of 5.28 as of fiscal year 2025, which is generally considered healthy.
What is Neuropace Inc's debt-to-equity ratio?
Neuropace Inc (NPCE) had a debt-to-equity ratio of 3.09 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Neuropace Inc's return on assets (ROA)?
Neuropace Inc (NPCE) had a return on assets of -20.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Neuropace Inc's cash runway?
Based on fiscal year 2025 data, Neuropace Inc (NPCE) had $21.7M in cash against an annual operating cash burn of $11.0M. This gives an estimated cash runway of approximately 24 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Neuropace Inc's Altman Z-Score?
Neuropace Inc (NPCE) has an Altman Z-Score of -2.01, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Neuropace Inc's Piotroski F-Score?
Neuropace Inc (NPCE) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Neuropace Inc's earnings high quality?
Neuropace Inc (NPCE) has an earnings quality ratio of 0.51x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Neuropace Inc cover its interest payments?
Neuropace Inc (NPCE) has an interest coverage ratio of -2.2x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Neuropace Inc?
Neuropace Inc (NPCE) scores 58 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.